Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 3
2022 2
2023 4
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. Turner D, et al. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. Gastroenterology. 2021. PMID: 33359090
BACKGROUND: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) has proposed treatment targets in 2015 for adult patients with inflammatory bowel disease …
BACKGROUND: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for …
How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?
Meade S, Routledge E, Sharma E, Honap S, Zeki S, Ray S, Anderson SHC, Sanderson J, Mawdsley J, Irving PM, Samaan MA. Meade S, et al. Frontline Gastroenterol. 2022 Dec 7;14(4):312-318. doi: 10.1136/flgastro-2022-102309. eCollection 2023. Frontline Gastroenterol. 2022. PMID: 37409343 Free PMC article.
Baseline characteristics: 62% male, median age 36.4 (27.8-43.9) years, disease distribution (L1: 4, L2: 11, L3: 35, perianal: 18). The proportion of patients achieving STRIDE-II end-points were: SES-CD 2-25 (50%) and >50% reduction in SES-CD-35 (70%). ...CONCLUSI …
Baseline characteristics: 62% male, median age 36.4 (27.8-43.9) years, disease distribution (L1: 4, L2: 11, L3: 35, perianal: 18). The propo …
Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions.
Tse CS, Hunt MG, Brown LA, Lewis JD. Tse CS, et al. Inflamm Bowel Dis. 2024 Mar 1;30(3):501-507. doi: 10.1093/ibd/izad182. Inflamm Bowel Dis. 2024. PMID: 37603844 Review.
The diagnosis of inflammatory bowel disease (IBD) is a life-changing moment for most adults. Biomedical advances over the past 2 decades have resulted in unprecedented growth of therapeutic options for IBD. ...Although the concept of IBD-related disabi …
The diagnosis of inflammatory bowel disease (IBD) is a life-changing moment for most adults. Biomedical advances over the past 2 …
Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases.
Dawwas GK, Weiss A, Constant BD, Parlett LE, Haynes K, Yang JY, Brensinger C, Wu Q, Pate V, Jonsson Funk M, Schaubel DE, Hurtado-Lorenzo A, David Kappelman M, Lewis JD. Dawwas GK, et al. Inflamm Bowel Dis. 2023 Dec 5;29(12):1993-1996. doi: 10.1093/ibd/izad053. Inflamm Bowel Dis. 2023. PMID: 37043675 Free PMC article. Review.
BACKGROUND: To facilitate inflammatory bowel disease (IBD) research in the United States, we developed and validated claims-based definitions to identify incident and prevalent IBD diagnoses using administrative healthcare claims data among multiple payers. ...We re …
BACKGROUND: To facilitate inflammatory bowel disease (IBD) research in the United States, we developed and validated claims-based def …
Therapeutic potential of enhancer of zeste homolog 2 in autoimmune diseases.
Yang YX, Shen HH, Cao F, Xie LY, Zhu GL, Sam NB, Wang DG, Pan HF. Yang YX, et al. Expert Opin Ther Targets. 2019 Dec;23(12):1015-1030. doi: 10.1080/14728222.2019.1696309. Epub 2019 Nov 28. Expert Opin Ther Targets. 2019. PMID: 31747802 Review.
Introduction: Autoimmune diseases (ADs) are idiopathic and heterogeneous disorders with contentious pathophysiology. Great strides have been made in epigenetics and its involvement in ADs. Zeste homolog 2 (EZH2) has sparked extensive interest because of its pleiotro …
Introduction: Autoimmune diseases (ADs) are idiopathic and heterogeneous disorders with contentious pathophysiology. Great strides ha …
Treatment endpoints in ulcerative colitis: Does one size fit all?
Mitrev N, Kariyawasam V. Mitrev N, et al. World J Gastrointest Pharmacol Ther. 2024 May 5;15(2):91591. doi: 10.4292/wjgpt.v15.i2.91591. World J Gastrointest Pharmacol Ther. 2024. PMID: 38764502 Free PMC article.
A treat-to-target strategy in inflammatory bowel disease (IBD) involves treatment intensification in order to achieve a pre-determined endpoint. ...However, choice of treatment endpoints remains a challenge in management of IBD via a treat-to-target strategy. The tr …
A treat-to-target strategy in inflammatory bowel disease (IBD) involves treatment intensification in order to achieve a pre-determine …
Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019.
Yang JY, Lund JL, Pate V, Kappelman MD. Yang JY, et al. Inflamm Bowel Dis. 2023 May 2;29(5):735-743. doi: 10.1093/ibd/izac136. Inflamm Bowel Dis. 2023. PMID: 35929644 Free PMC article.
BACKGROUND: Evaluation of mucosal healing with colonoscopy is recommended for inflammatory bowel disease (IBD) management; however, little is known about real-world use of treat-to-target monitoring following IBD treatment initiation. ...RESULTS: From 2013 to 2019, …
BACKGROUND: Evaluation of mucosal healing with colonoscopy is recommended for inflammatory bowel disease (IBD) management; however, l …
P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
Brunt H, Hamer D, Chapman C. Brunt H, et al. Am J Gastroenterol. 2021 Dec 1;116(Suppl 1):S2-S3. doi: 10.14309/01.ajg.0000798636.78132.29. Am J Gastroenterol. 2021. PMID: 37461929
Currently, there is no standard of care for disease monitoring in IBD. Society guidelines and the STRIDE program have recommendations on the use of patient reported outcomes (PRO), biomarkers, and endoscopy in disease monitoring. ...We performed a literature review …
Currently, there is no standard of care for disease monitoring in IBD. Society guidelines and the STRIDE program have recommen …
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF, Schreiber S, D'Haens G, Rizzo J, Kligys K, Griffith J, Zambrano J, Zhou Q, Zhang Y, Kalabic J, Rieder F, Dubinsky MC, Panaccione R. Colombel JF, et al. J Crohns Colitis. 2024 Jun 3;18(6):818-827. doi: 10.1093/ecco-jcc/jjad206. J Crohns Colitis. 2024. PMID: 38069472 Free PMC article. Clinical Trial.
Stool frequency [SF] and abdominal pain score [APS] are patient-reported outcomes [PROs] measuring symptom severity, which are supported as treatment targets by the STRIDE-II consensus. This post hoc analysis examined the efficacy of risankizumab [RZB], a humanised monoclo …
Stool frequency [SF] and abdominal pain score [APS] are patient-reported outcomes [PROs] measuring symptom severity, which are supported as …
Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis.
Jangi S, Holmer AK, Dulai PS, Boland B, Valasek M, Jairath V, Feagan BG, Sandborn WJ, Singh S. Jangi S, et al. Clin Gastroenterol Hepatol. 2022 Apr;20(4):e750-e760. doi: 10.1016/j.cgh.2021.02.007. Epub 2021 Feb 6. Clin Gastroenterol Hepatol. 2022. PMID: 33556578 Free PMC article.
RESULTS: Of 86 patients with moderate to severely active pancolitis who underwent 2 consecutive colonoscopies during treat-to-target interventions, 38% and 51% achieved histologic and endoscopic remission, respectively. ...
RESULTS: Of 86 patients with moderate to severely active pancolitis who underwent 2 consecutive colonoscopies during treat-to-target …
15 results